Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. Todos Med Ltd. (TOMDF) Message Board

What Petrosino Assvisors aren't telling their Weal

Message Board Public Reply | Private Reply | Keep | Replies (1)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 1418
(Total Views: 242)
Posted On: 03/09/2022 10:32:41 AM
Avatar
Posted By: redspeed
What Petrosino Assvisors aren't telling their Wealth Inhibitor clients

Todos Market Cap is sitting at $25M right now

Through the first nine months of 2021, revenue was $7,77M. Let's say very conservatives revenue comes in at a nice even $10M for 2021. That puts the company at a 2.5 multiple of revenue. If they get the money owed to them, than it could be a 2x multiple.

Pick another company. Inventiva SA's (NASDAQ: IVA) popped up with news yesterday so lets use that.

The FDA has completed a safety review of Inventiva SA's (NASDAQ: IVA) IND application and signed off Phase 2 combination trial with its lead drug candidate, lanifibranor.

The planned Phase 2 trial, LEGEND3, has been designed as a proof-of-concept trial to assess the safety and efficacy of lanifibranor combined with empagliflozin for non-cirrhotic NASH and Type 2 Diabetes (T2D).

LEGEND is expected to recruit a total of 63 non-cirrhotic non-alcoholic steatohepatitis (NASH) patients with T2D.


Huh, only 63 patients? Petrosino Assvisors & Friends thought you should have 10,000s in all phase II trials. Oh and this is just a POC and not even of double blind BTW

For the 2021 fiscal year, Inventiva's revenues amounted to €4.2 million compared to €0.4 million for 2020 primarily due to the payment to the Company of €4.0 million for a milestone reached at the end of 2021, and received on January 31, 2022, following the launch by AbbVie of the Phase IIb clinical trial with cedirogant in the fourth quarter of 2021.

R&D expenses doubled for the fiscal year ended December 31, 2021 €48.4 million compared to €23.7 million for the same period in 2020

General and administrative expenses (G&A) amounted to €11.2 million for the fiscal year ended December 31, 2021, an increase of 31% compared to €8.5 million

The Company’s net loss stood at €49.6 million as of December 31,2021 compared to €33.6 million as of December 31, 2020

Implementation of an At-The-Market (“ATM”) program in the United States for the sale up to $100 m of ADS


Inventiva's Market Cap $460M

So their revenue is 1/2 of Todos, cap is nearly 20 times that of Todos

In fact, their cap is 100x revenue and it's down a bit

They are ringing up cash out of the ATM

Burning through money

$50M net loss

10's of millions of debt and liabilities

I could go on but you probably get the point

Oh, and they have no commercial products

inventiva-pipeline-07-02-2022.png

This was just picking a company at random

Let's see, if Todos was valued at x100 revenue, that would be $1B

So when someone says the stock is going to trips. I can see those zeros

Triple trips +$1,000,000,000

Not today, nor tomorrow, but the value right now is beginning manipulated on the OTC. You can see it when you look at the trades. You can easily see it when you look at other stocks

Earnings release is 3 weeks or less away. Won't have long to wait.

Do you own DD and don't get it off a messageboard or Petrosino Assvisors & Wealth Inhibitors.









(3)
(0)




Todos Med Ltd. (TOMDF) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us